Spots Global Cancer Trial Database for Safety Study of Thioridazine in Combination With Cytarabine to Treat Relapsed or Refractory Acute Myeloid Leukemia
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety Study of Thioridazine in Combination With Cytarabine to Treat Relapsed or Refractory Acute Myeloid Leukemia
Official Title: A Phase I Trial Evaluating Oral Thioridazine in Combination With Intermediate Dose Cytarabine in Patients 55 Years and Older With Acute Myeloid Leukemia Who Have Relapsed or Have Refractory Disease
Study ID: NCT02096289
Conditions
Interventions
Study Description
Brief Summary: This is a Phase I trial investigating the safety of using thioridazine in addition to cytarabine in elderly patients with relapsed or refractory Acute Myeloid Leukemia.
Detailed Description:
Eligibility
Minimum Age: 55 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Juravinski Hospital & Cancer Centre, Hamilton, Ontario, Canada
Contact Details
Name: Mark N Levine, MD
Affiliation: Ontario Clinical Oncology Group, McMaster University
Role: STUDY_DIRECTOR
Name: Ronan Foley, MD
Affiliation: Hamilton Health Sciences, McMaster University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
